Philip Morris International Inc. and its subsidiary Swedish Match North America LLC are asking a Connecticut federal judge to ...

In September 2024, the U.S. Food and Drug Administration (FDA) issued three guidance documents to support different clinical ...

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

As the rate of myopia in children grows, research is keeping a finger pointed at the fact much of our lives is spent indoors.

The U. S. Food and Drug Administration (FDA) has signed off on Cobenfy, the first revolutionary treatment for schizophrenia ...

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD, and makes ...

The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...

The U.S. Food and Drug Administration warns customers to not feed their pets certain lots of these pet food brands as they ...

Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share.

AbbVie on Friday said the application covers telisotuzumab vedotin, or teliso-V, in adults with previously treated, locally advanced or metastatic epidermal growth factor receptor wild type, ...

Babies conceived through assisted reproductive technology are more likely to be born with a major heart defect, new research ...

Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...